Overview

Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
To prevent recurrence of invasive fungal infection in patients with allogeneic stem cell transplants
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer
Collaborators:
European Group for Blood and Marrow Transplantation
European Society for Blood and Marrow Transplantation
Treatments:
Voriconazole